A Phase I Study of G3139 (NSC 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML) 60 Years of Age.
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Oblimersen (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Adverse reactions
- 05 Sep 2005 New trial record.